Phase 3 DESTINY-Lung04 Trial Shows First-Line Trastuzumab Deruxtecan Significantly Improves Progression-Free Survival in HER2-Mutant NSCLC
Phase 3positivetrastuzumab deruxtecanpembrolizumabPositive
AI Analysis
Summary
DESTINY-Lung04 Phase 3 trial demonstrates trastuzumab deruxtecan significantly improves median progression-free survival to 14.3 months compared to 8.3 months with pembrolizumab plus chemotherapy in first-line HER2-mutant NSCLC treatment.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Median PFS of 14.3 months with T-DXd versus 8.3 months with pembrolizumab plus chemotherapy
Importance:8/10
Sentiment:
0.85
Phase 3 trialNSCLCHER2-mutantfirst-line treatmentprogression-free survivalimmunotherapy
Related Companies
Read the original article
Published by PR Newswire Biotech on September 14, 2026 2:25 PM